Skip to main content

Resilient sales and business EPS in Q3 2010

Pressmeddelande   •   Okt 28, 2010 16:55 CEST

Commenting on the Group’s performance in Q3 2010, sanofi-aventis Chief Executive Officer, Christopher A. Viehbacher said, “This third quarter was marked by the success of the Jevtana® launch in the U.S., by positive Phase III data for lixisenatide and teriflunomide but also by the entry of a generic of Lovenox® in the U.S. Our Q3 results were also enhanced by favourable currency tailwind. Tight cost control and good performance of growth platforms have allowed the Group to slightly raise its guidance for 2010. In addition, we recently commenced a tender offer to acquire Genzyme.”

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, please visit: www.sanofi-aventis.com

Bifogade filer

PDF-dokument